A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors
Status:
Completed
Trial end date:
2019-04-03
Target enrollment:
Participant gender:
Summary
This first-in-human study of AMG 900 will be conducted in two parts: dose escalation and dose
expansion. The dose escalation part of the study is aimed at evaluating the safety,
tolerability and PK of oral AMG 900 in subjects with advanced solid tumors. Up to 50 subjects
may be enrolled in dose escalation. The dose expansion part of the study will consist of 42
subjects in three taxane-resistant tumor types. The dose of AMG 900 will be dependent upon
data from the dose escalation part of the study